Gilead Sciences, Inc., a biopharmaceutical company that develops, manufactures, and commercializes therapies for viral, infectious, and cancer diseases, has acquired all of the outstanding common shares in CV Therapeutics, Inc., a biopharmaceutical company focused on the development of small molecule drugs for the treatment of cardiovascular diseases.